Lyudmila Bazhenova Selected Research

sitravatinib

10/2022

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lyudmila Bazhenova Research Topics

Disease

30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 04/2010
25	Neoplasms (Cancer) 10/2022 - 01/2013
15	Lung Neoplasms (Lung Cancer) 09/2021 - 04/2011
6	Disease Progression 09/2021 - 02/2006
4	Neoplasm Metastasis (Metastasis) 01/2022 - 04/2014
4	Circulating Neoplastic Cells 02/2015 - 02/2012
3	Diarrhea 01/2022 - 10/2019
2	Adenocarcinoma of Lung 03/2022 - 09/2017
2	Exanthema (Rash) 01/2022 - 01/2018
2	Hypertension (High Blood Pressure) 01/2020 - 10/2019
1	Colorectal Neoplasms (Colorectal Cancer) 10/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 03/2022
1	Body Weight (Weight, Body) 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	Neutropenia 01/2022
1	Hyperglycemia 02/2021
1	Vomiting 02/2021
1	Hyponatremia 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Proteinuria 10/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Epilepsy (Aura) 01/2019
1	Fatigue 01/2018
1	Carcinogenesis 01/2018
1	Acne Vulgaris 01/2018
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018
1	Melanoma (Melanoma, Malignant) 11/2017
1	Pulmonary Embolism 12/2016
1	Thrombocytopenia (Thrombopenia) 12/2016
1	Thrombosis (Thrombus) 02/2015
1	Venous Thromboembolism 02/2015
1	Genomic Instability 01/2015
1	Hypersensitivity (Allergy) 12/2014
1	Mesothelioma 12/2014
1	Malignant Mesothelioma 12/2014

Drug/Important Bio-Agent (IBA)

8	ErbB Receptors (EGF Receptor)IBA 03/2022 - 03/2015
6	Phosphotransferases (Kinase)IBA 10/2022 - 04/2010
6	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2013
5	Tyrosine Kinase InhibitorsIBA 03/2022 - 12/2016
4	PlatinumIBA 01/2022 - 02/2021
3	TropomyosinIBA 01/2022 - 01/2018
3	Pharmaceutical PreparationsIBA 01/2022 - 03/2015
3	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2017
3	osimertinibIBA 01/2019 - 12/2016
2	adagrasibIBA 10/2022 - 01/2022
2	entrectinibIBA 05/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 03/2022 - 07/2009
2	B7-H1 AntigenIBA 01/2022 - 01/2017
2	amivantamab-vmjwIBA 01/2022 - 01/2022
2	NivolumabIBA 09/2021 - 01/2021
2	Pemetrexed (MTA)FDA Link 02/2021 - 12/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 01/2021
2	selpercatinibIBA 01/2021 - 01/2020
2	Alanine Transaminase (SGPT)IBA 01/2020 - 12/2016
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2019 - 01/2017
2	Biological ProductsIBA 01/2019 - 04/2014
2	AntibodiesIBA 01/2018 - 08/2014
2	Circulating Tumor DNAIBA 10/2017 - 09/2017
2	Keratins (Keratin)IBA 01/2017 - 08/2014
1	c-Mer Tyrosine KinaseIBA 10/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2022
1	sitravatinibIBA 10/2022
1	pembrolizumabIBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	trastuzumab deruxtecanIBA 01/2022
1	palbociclibIBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	avelumabIBA 01/2022
1	alectinibIBA 10/2021
1	IpilimumabIBA 09/2021
1	Gemcitabine FDA Link 02/2021
1	Docetaxel (Taxotere)FDA Link 02/2021
1	rociletinibIBA 02/2021
1	tyrosine receptor (receptor, tyrosine)IBA 01/2021
1	DV281IBA 01/2021
1	veliparibIBA 01/2021
1	Carboplatin (JM8)FDA LinkGeneric 01/2021
1	mobocertinibIBA 01/2021
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	Bevacizumab (Avastin)FDA Link 10/2019
1	eosinylphosphatidylethanolamine (EOPE)IBA 01/2019
1	agerafenibIBA 01/2019
1	Cetuximab (Erbitux)FDA Link 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2018
1	insulin receptor tyrosine kinaseIBA 01/2017
1	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2017
1	SteroidsIBA 12/2016
1	vinyltriethoxysilane (VTES)IBA 02/2015
1	Thromboplastin (Tissue Factor)IBA 02/2015
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2015
1	Monoclonal AntibodiesIBA 12/2014
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 12/2014
1	amatuximabIBA 12/2014
1	Cisplatin (Platino)FDA LinkGeneric 12/2014

Therapy/Procedure

18	Therapeutics 03/2022 - 02/2006
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
5	Radiotherapy 01/2018 - 04/2011
4	Immunotherapy 09/2021 - 01/2017
1	Chemoradiotherapy 01/2021
1	Precision Medicine 10/2017